Subsidiary HDM1005 of Huadong Medicine(000963.SZ) has received approval notification for a new drug clinical trial from the US FDA.

Huadong Medicine (000963.SZ) announced that its wholly-owned subsidiary, Hangzhou Zhenmei Huadong Pharmaceutical Co., Ltd. (referred to as "Zhenmei Huadong"), recently received a notification from the U.S. Food and Drug Administration (FDA) that the clinical trial application for HDM1005 injection developed by Zhenmei Huadong has been approved by the FDA for Phase I clinical trials in the United States. HDM1005 injection is a dual-target long-acting agonist of peptide human GLP-1 receptor and GIP receptor. GLP-1 products have effects such as weight loss, blood sugar reduction, and cardiovascular benefits and are relatively mature and safe targets. The approval of the clinical trial for HDM1005 injection is another important progress in the development process of this product, which will further enhance the company's core competitiveness in the field of endocrine therapy.